Basic Information
Isturisa
Regulatory Information
EMEA/H/C/004821
Authorised
January 9, 2020
November 14, 2019
7
December 12, 2024
Company Information
France
Immeuble le Wilson 70, avenue du Général de Gaulle 92800 Puteaux
RECORDATI RARE DISEASES
Drug Classification
Orphan Medicine
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Isturisa is indicated for the treatment of endogenous Cushing’s syndrome in adults.
Overview Summary
Isturisa is a medicine used to treat adults with Cushing’s syndrome, a disease characterised by an excess production of the hormone cortisol by the adrenal glands, two glands situated above the kidneys. Cushing’s syndrome is rare, and Isturisa was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 15 October 2014. Isturisa contains the active substance osilodrostat.